Publication de 4 numéros par an
ISSN Imprimer: 2694-4642
ISSN En ligne: 2694-4650
Indexed in
CD20 and Its Antibodies: Past, Present, and Future
Get access
RÉSUMÉ
The pan B-cell marker CD20 was cloned more than 3 decades ago. It has been intensively studied ever since, allowing the specific identification and targeting of B cells facilitating the development of antibody-mediated immunotherapy. In this review, we document the current understanding of how CD20 regulates B-cell biology. We also describe the emerging knowledge of how anti-CD20 antibodies elicit their therapeutic responses, revealing how this has changed and matured throughout the decades of their use.
-
Yu Xiaojie, Marshall Michael J. E., Cragg Mark S., Crispin Max, Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering, BioDrugs, 31, 3, 2017. Crossref
-
Marshall Michael J. E., Stopforth Richard J., Cragg Mark S., Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?, Frontiers in Immunology, 8, 2017. Crossref
-
Casan J. M. L., Wong J., Northcott M. J., Opat S., Anti-CD20 monoclonal antibodies: reviewing a revolution, Human Vaccines & Immunotherapeutics, 14, 12, 2018. Crossref
-
Hofmann Katharina, Clauder Ann-Katrin, Manz Rudolf Armin, Targeting B Cells and Plasma Cells in Autoimmune Diseases, Frontiers in Immunology, 9, 2018. Crossref
-
Pecoraro Antonio, Crescenzi Ludovica, Galdiero Maria Rosaria, Marone Giancarlo, Rivellese Felice, Rossi Francesca Wanda, de Paulis Amato, Genovese Arturo, Spadaro Giuseppe, Immunosuppressive therapy with rituximab in common variable immunodeficiency, Clinical and Molecular Allergy, 17, 1, 2019. Crossref
-
Liu Rena, Oldham Robert, Teal Emma, Beers Stephen, Cragg Mark, Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment, Antibodies, 9, 4, 2020. Crossref